Officials involved in good manufacturing practice (GMP) in 10 member nations of the Association of South East Asian Nations(ASEAN) have recently visited JW Pharmaceutical’s JW중외제약 factory compound in Dangjin, South Chungcheong Province.
JW Pharmaceutical said Wednesday 19 GMP-related officials from 10 ASEAN members -- Indonesia, Malaysia, the Philippines, Singapore, Brunei, Laos, Cambodia, Myanmar, Thailand, and Vietnam -- visited the complex and looked around facilities and the processes to produce medical products.
The Ministry of Food and Drug Safety (MFDS)식품의약품안전처 and Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA)한국제약바이오협회 organized the visit as part of “Education of Korea-ASEAN GMP inspector of medical products” program, designed to publicize the excellence of Korean pharmaceutical industry and expand the Asian markets for Korean medicines.
The complex has Korea’s first factory to produce penem antibiotics and the world’s biggest non-PVC fluid plant. The plant, designed to comply with cGMP and the quality management standard for medical products, produces 120 million units of fluid, 130 million injections, 1.3 billion solid formations, and 16 million asepsis annually.
“We will do our best to enter the Southeast Asian market by communicating with ASEAN countries that want to adopt an advanced manufacturing system of medical products,” said an official at JW Pharmaceutical.
<© Korea Biomedical Review, All rights reserved.>